News RA pill setback spoils Lilly’s growth story Eli Lilly has posted a strong 8% increase in sales for the second quarter, led by grow
News AbbVie looks beyond Humira as RA pill meets phase 3 targets Upadacitinib hopes drug will reduce reliance on Humira.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
